FCN 016
Alternative Names: FCN-016Latest Information Update: 04 Apr 2023
At a glance
- Originator Shanghai Fosun Pharmaceutical
- Class Antiglaucomas
- Mechanism of Action Rho-associated kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glaucoma
Most Recent Events
- 27 Mar 2023 Preclinical trials in Glaucoma in China Prior to March 2023(Shanghai Fosun Pharmaceutical pipeline, March 2023)